TOP-5 Analyst Price Targets as of 23.06.26

Definium Therapeutics [CA24477V1058] Canaccord reiterates Buy rating and raises price target from $38 to $60 (75% upside potential) Canaccord is significantly more optimistic about the prospects of DT120 following the positive Phase 3 results of the EMERGE study. The compelling data in major depression has, according to the analysts, noticeably reduced the clinical risk of the program and increased the likelihood of future approval. Furthermore, the experts view the results not just as a success for the depression indication but also as an important...